ANVS on NYSE
Annovis Bio, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-171.2%Return on equity3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $25.2M | $20.0M |
| General and administrative | $4.5M | $6.7M |
| Total operating expenses | $29.7M | $26.7M |
| Operating loss | -$29.7M | -$26.7M |
| Interest income | $699.1K | $331.8K |
| Other financing costs | -$1.9M | |
| Change in fair value of warrants | $142.0K | $3.6M |
| Total other income, net | $841.1K | $2.1M |
| Net loss | -$28.9M | -$24.6M |
| Basic (dollars per share) | -$1.40 | -$2.02 |
| Diluted (dollars per share) | -$1.40 | -$2.31 |
| Basic | 20.6M shares | 12.2M shares |
| Diluted | 20.6M shares | 12.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $19.5M | $10.6M | |
| Prepaid expenses and other current assets | $1.5M | $3.4M | |
| Total assets | $21.1M | $13.9M | |
| Accounts payable | $2.6M | $2.3M | |
| Accrued expenses | $1.0M | $1.6M | |
| Total current liabilities | $3.6M | $3.9M | |
| Warrant liability | $595.0K | $737.0K | |
| Total liabilities | $4.2M | $4.6M | |
| Common stock - $0.0001 par value, 70,000,000 shares authorized, 27,199,139 and 14,141,521 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $2.7K | $1.4K | |
| Additional paid-in capital | $180.6M | $144.2M | |
| Accumulated deficit | -$163.7M | -$134.8M | |
| Total stockholders' equity | $16.9M | $9.3M | -$7.8M |
| Total liabilities and stockholders' equity | $21.1M | $13.9M | |
| Preferred stock, par value (dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value (dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 70.0M shares | 70.0M shares | |
| Common stock, shares issued | 27.2M shares | 14.1M shares | |
| Common stock, shares outstanding | 27.2M shares | 14.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$28.9M | -$24.6M |
| Stock-based compensation expense | $1.8M | $3.8M |
| Change in fair value of warrants | -$142.0K | -$3.6M |
| Non-cash other financing costs | $1.8M | |
| Prepaid expenses and other current assets | $1.8M | $1.1M |
| Accounts payable | $284.5K | $1.0M |
| Accrued expenses | -$530.2K | -$1.4M |
| Net cash used in operating activities | -$25.6M | -$21.9M |
| Proceeds from issuance of common stock, warrants, and pre-funded warrants, net | $34.6M | $18.7M |
| Proceeds from exercise of common stock options, net | $2.0K | $0 |
| Proceeds from exercise of warrants | $8.0M | |
| Net cash provided by financing activities | $34.6M | $26.7M |
| Net increase in cash and cash equivalents | $9.0M | $4.8M |
| Reduction in value of warrants related to exercises | $9.3M | |
| Cash paid for financing costs | $50.0K |
Former names
- QR Pharma, Inc.Jan 15, 2010 to Mar 15, 20192
Recent filings
- Oct 7, 2026DEFA14A
- Sep 11, 2026DEF 14A
- Aug 25, 2026PRE 14A
- Aug 14, 2026SCHEDULE 13G
- Aug 14, 20268-K
- Aug 14, 202610-Q
- Jul 29, 2026SCHEDULE 13G
- Jul 10, 20268-K
- Jun 17, 20268-K
- May 21, 20264 OWNERSHIP DOCUMENT
- May 20, 2026424B5
- May 20, 20268-K
- May 19, 2026424B5
- May 15, 20268-K
- May 15, 202610-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11